{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:59:08Z","timestamp":1790287148716,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00633X\/1"],"award-info":[{"award-number":["MR\/N00633X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Primary Care"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lanprc.2026.100139","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:41:16Z","timestamp":1776372076000},"page":"100139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5686-5033","authenticated-orcid":false,"given":"Thijs T","family":"Jansz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-3864","authenticated-orcid":false,"given":"Katherine G","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8545-5833","authenticated-orcid":false,"given":"Martha M","family":"Dinsdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley M","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-7599","authenticated-orcid":false,"given":"Angus G","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Oram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanprc.2026.100139_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.15585\/mmwr.mm7111a3","article-title":"Reported cases of end-stage kidney disease\u2014United States, 2000\u20132019","volume":"71","author":"Burrows","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanprc.2026.100139_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lanprc.2026.100139_bib3","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanprc.2026.100139_bib4","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanprc.2026.100139_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanprc.2026.100139_bib6","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lanprc.2026.100139_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","article-title":"Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","volume":"24","author":"Chaiyakunapruk","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lanprc.2026.100139_bib8","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium\u2013glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lanprc.2026.100139_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.lanprc.2026.100139_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","article-title":"Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Colombijn","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/j.lanprc.2026.100139_bib11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.lanprc.2026.100139_bib12","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanprc.2026.100139_bib13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lanprc.2026.100139_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.lanprc.2026.100139_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017989","article-title":"Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes","volume":"7","author":"Rodgers","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanprc.2026.100139_bib16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.lanprc.2026.100139_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.lanprc.2026.100139_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lanprc.2026.100139_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lanprc.2026.100139_bib20","article-title":"The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study","volume":"13","author":"Al-Mashhadi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lanprc.2026.100139_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanprc.2026.100139_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"key":"10.1016\/j.lanprc.2026.100139_bib23","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanprc.2026.100139_bib24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/dc22-0698","article-title":"Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes","volume":"45","author":"Grams","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanprc.2026.100139_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanprc.2026.100139_bib26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/01621459.1986.10478280","article-title":"Multiple imputation for interval estimation from simple random samples with ignorable nonresponse","volume":"81","author":"Rubin","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lanprc.2026.100139_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-087179","article-title":"Transparent reporting of observational studies emulating a target trial: the TARGET Statement","volume":"390","author":"Cashin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.lanprc.2026.100139_bib28","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.kint.2024.03.019","article-title":"Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect","volume":"105","author":"Yau","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.lanprc.2026.100139_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.lanprc.2026.100139_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00125-025-06577-2","article-title":"Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection","volume":"69","author":"Jansz","year":"2026","journal-title":"Diabetologia"}],"container-title":["The Lancet Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050514326000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050514326000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:01:41Z","timestamp":1790283701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050514326000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S3050514326000348"],"URL":"https:\/\/doi.org\/10.1016\/j.lanprc.2026.100139","relation":{},"ISSN":["3050-5143"],"issn-type":[{"value":"3050-5143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data","name":"articletitle","label":"Article Title"},{"value":"The Lancet Primary Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanprc.2026.100139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100139"}}